aTyr Pharma (ATYR) vs Cel-Sci (CVM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
aTyr Pharma (ATYR) has outperformed Cel-Sci (CVM) over the past year, losing 74.5% versus a loss of 80.6%. Over five years, ATYR leads with a -97.1% price change compared with -99.4% for CVM. Cel-Sci is the larger company by market cap ($34.1 million vs $24.1 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATYR | CVM |
|---|---|---|
| Share price | $0.2462 | $1.94 |
| Market cap | $24.15M | $34.12M |
| 1-day change | -3.56% | -0.51% |
| YTD return | -67.39% | -62.93% |
| 1-year return | -74.47% | -80.56% |
| 5-year return | -97.07% | -99.38% |
| EPS (TTM) | $-0.62 | $-1.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.12 | $10.24 |
| 52-week low | $0.246 | $0.89 |
| Distance from 52-week high | -78.02% | -81.05% |
| Analyst consensus | buy | none |
| Avg. price target upside | +1061.66% | +544.33% |
| Average volume | 3.24M | 243.94K |
| Shares outstanding | 98.09M | 17.59M |
| Employees | 58 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About aTyr Pharma
ATYR stock →aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 58 employees
About Cel-Sci
CVM stock →CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
ATYR vs CVM FAQ
Which is bigger, aTyr Pharma or Cel-Sci?
Cel-Sci (CVM) is larger, with a market capitalization of $34.12M compared with $24.15M for aTyr Pharma (ATYR).
Which stock has performed better over the past year, ATYR or CVM?
ATYR returned -74.47% over the past 12 months, compared with -80.56% for CVM (price return, excluding dividends). Past performance does not predict future results.
Are aTyr Pharma and Cel-Sci in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.